Article Details

Spark Therapeutics' (ONCE) “Underperform” Rating Reaffirmed at Credit Suisse Group

Retrieved on: 2018-08-11 00:35:15

Tags for this article:

Click the tags to see associated articles and topics

Spark Therapeutics' (ONCE) “Underperform” Rating Reaffirmed at Credit Suisse Group. View article details on hiswai:

Excerpt

<div><b>Sofinnova Ventures</b> Inc acquired a new position in shares of Spark Therapeutics during the 1st quarter valued at about $32,048,000. Rockefeller ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo